Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. ⋯ Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialOmalizumab is effective in the long-term control of severe allergic asthma.
Previous reports show that addition of omalizumab to standard therapy reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids (ICSs) and rescue medication in patients with allergic asthma. ⋯ These results indicate that omalizumab is effective in the long-term control of severe allergic asthma.
-
Ann. Allergy Asthma Immunol. · Aug 2003
Randomized Controlled Trial Multicenter Study Clinical TrialEvaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
To evaluate the long-term effects of the anti-IgE antibody omalizumab in children with asthma. ⋯ Long-term treatment with omalizumab is safe and well tolerated in children with allergic asthma.